Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Sentiment | Market Cap | Shares | Institutional % | Insider % | Net Insider (L12M) | Net Insider (L3M) |
|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $7.40B | 105,371,729 | 28.90% | 71.10% | Net Buying | Net Selling | ||
| TGTX | TG THERAPEUTICS INC | $4.43B | 158,665,613 | 56.33% | 43.67% | Net Selling | Net Selling | ||
| CRMD | CORMEDIX INC | $885.79M | 67,824,659 | 50.33% | 9.81% | Net Selling | |||
| GYRE | GYRE THERAPEUTICS INC | $725.24M | 96,313,157 | 2.05% | 97.95% | Net Buying | Net Selling | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $2.46B | 74,107,668 | 53.73% | 9.47% | Net Selling | Net Selling | ||
| KRYS | KRYSTAL BIOTECH INC | $4.17B | 28,942,981 | 78.73% | 21.27% | Net Selling | Net Selling | ||
| HALO | HALOZYME THERAPEUTICS INC | $8.19B | 116,966,000 | 77.19% | 22.81% | Net Selling | Net Selling | ||
| EXEL | EXELIXIS INC | $10.10B | 269,202,521 | 94.43% | 5.32% | Net Selling | Net Selling | ||
| RPRX | ROYALTY PHARMA PLC | $20.99B | 583,174,298 | 58.52% | 17.24% | Net Selling | Net Selling | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.58B | 131,629,546 | 44.04% | 12.63% | Net Buying | Net Buying | ||
| INVA | INNOVIVA INC | $1.29B | 63,021,014 | 59.66% | 40.34% | Net Selling | |||
| VCEL | VERICEL CORP | $1.83B | 50,460,205 | 91.44% | 8.56% | Net Selling | Net Buying | ||
| ARGX | ARGENX SE | $40.09B | 61,034,202 | 52.64% | 0.00% | ||||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.09B | 57,532,601 | 70.49% | 29.51% | Net Selling | Net Selling | ||
| INCY | INCYTE CORP | $16.69B | 195,276,145 | 77.46% | 22.54% | Net Selling | Net Selling | ||
| ADMA | ADMA BIOLOGICS INC | $4.16B | 238,630,719 | 78.55% | 21.45% | Net Selling | Net Selling | ||
| MNKD | MANNKIND CORP | $1.22B | 306,828,335 | 35.15% | 64.85% | Net Selling | Net Selling | ||
| ATRA | ATARA BIOTHERAPEUTICS INC | $80.62M | 7,023,032 | 13.57% | 86.43% | Net Buying | Net Buying | ||
| MDXG | MIMEDX GROUP INC | $1.06B | 147,959,416 | 46.30% | 53.70% | Net Buying | Net Buying | ||
| TECH | BIO-TECHNE CORP | $8.60B | 156,767,295 | 97.62% | 2.38% | Net Buying | Net Buying | ||
| VCYT | VERACYTE INC | $2.32B | 78,314,611 | 66.66% | 33.34% | Net Selling | Net Selling | ||
| NVO | NOVO NORDISK A S | $244.59B | 4,465,000,000 | 6.84% | 0.00% | ||||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.00B | 192,014,601 | 95.55% | 1.74% | Net Selling | |||
| NAGE | NIAGEN BIOSCIENCE INC | $768.02M | 79,752,957 | 17.09% | 82.91% | Net Buying | |||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.48B | 122,391,010 | 82.57% | 15.77% | Net Buying | Net Selling | ||
| GMAB | GENMAB A | $15.28B | 64,154,254 | 99.28% | 0.00% | ||||
| VRTX | VERTEX PHARMACEUTICALS INC | $100.19B | 256,390,651 | 93.65% | 1.51% | Net Selling | Net Selling |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.